Scrip senior writer Joseph Haas and PwC analyst Roel Van den Akker look back on biopharma sector dealmaking in 2025, why deal values rose from 2024's lows, and look ahead to what the trends mean heading into 2026 in this latest edition of the Scrip M&A Podcast.

Scrip senior writer Joseph Haas and PwC analyst Roel Van den Akker look back on biopharma sector dealmaking in 2025, why deal values rose from 2024's lows, and look ahead to what the trends mean heading into 2026 in this latest edition of the Scrip M&amp;A Podcast.

Scrip M&A Podcast: PwC's Dealmaking Preview for 2026

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Share Scrip M&A Podcast: PwC's Dealmaking Preview for 2026

Sign up to save your podcasts

Scrip M&A Podcast: PwC's Dealmaking Preview for 2026

Scrip M&A Podcast: PwC's Dealmaking Preview for 2026

More shows like Citeline Podcasts

Marketplace Tech

WSJ Your Money Briefing

WSJ What’s News

Bloomberg Intelligence

HBR IdeaCast

How to Be Awesome at Your Job

GZERO World with Ian Bremmer

The Readout Loud

Thoughts on the Market

The Journal.

The Next Big Idea

BioCentury This Week

Coaching Real Leaders

Biotech Hangout

HBR On Leadership